不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HTLV-1 持续存在的免疫学方面；用于成人 T 细胞白血病-淋巴瘤（ATL）的预防和治疗
英文原题：Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).
查看英文原题
Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
人类T细胞白血病病毒1型（HTLV-1）在约5%的慢性感染者中引起高度侵袭性的恶性肿瘤——成人T细胞白血病-淋巴瘤（ATL）。尽管存在强烈的免疫反应，HTLV-1仍通过增强感染T细胞的存活而在宿主体内持续存在。因此，无症状HTLV-1携带者终生处于感染细胞增殖与宿主抗病毒免疫反应之间的平衡状态。然而，这种免疫平衡在ATL患者中丧失。目前缺乏可靠的治疗选择，迫切需要新的治疗策略以改善ATL的不良预后。在这篇综述中，我们总结了目前关于HTLV-1持续存在的免疫学方面以及ATL中观察到的免疫改变的知识，并讨论了近年来过继性免疫治疗的进展如何为ATL提供预防和治疗选择。
展开英文摘要原文
Human T-cell leukaemia virus type-1 (HTLV-1) causes the highly aggressive malignancy adult T-cell leukaemia-lymphoma (ATL) in approximately 5 % of chronically infected carriers. HTLV-1 persists in the host by enhancing survival of infected-T-cells despite the presence of a strong immune response.
Therefore, asymptomatic HTLV-1 carriers have a lifelong balance between infected cell proliferation and the host antiviral immune response.
However, this immunological balance is lost in patients with ATL. Reliable treatment options are lacking and there is urgent need for new treatment strategies to improve the dismal prognosis of ATL. In this review, we present a summary of the current knowledge on the immunological aspects of HTLV-1 persistence and the immune alterations observed in ATL, and discuss how the recent emerging advances in adoptive immunotherapy may offer a prevention and treatment option for ATL.
论文信息
- 作者
- Weterings DA、Rowan AG、Cook LB
- 第一作者单位
- Department of Infectious Diseases, Faculty of Medicine, Imperial College London, UK.United Kingdom
- 通讯作者单位
- National Centre for Human Retrovirology and Department of Haematology, Imperial College Healthcare NHS Trust, UK; Department of Immunology & Inflammation, Imperial College London, UK. Electronic address: l.cook@imperial.ac.uk.United Kingdom
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Leukemia research2025 Jan
- 原文标识
- PubMed 39642764 · DOI 10.1016/j.leukres.2024.107635